The invention relates to substituted S-alaninate derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
2.
NEW CHEMICAL PROCESS FOR THE PRODUCTION OF 4-(4-FLUORO-2-METHYL-PHENYL)-5-NITRO- 1H-PYRIDIN-2-ONE, A KEY INTERMEDIATE OF ELINZANETANT
The present invention relates to a process for producing 4-(4-fluoro-2-methyl-phenyl)-5- nitro-1H-pyridin-2-one, a key intermediate of 2-[3,5-bis(trifluoromethyl)phenyl]-N-{4-(4- fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1- c][1,4]oxazin-8(1H)-yl]pyridin-3-yl}-N,2-dimethylpropanamide (elinzanetant). Further, the invention relates to a compound of Formula (VII): [Formula should be inserted] wherein R1144-alkyl or optionally substituted phenyl; a compound being 3-(4- fluoro-2-methyl-phenyl)-4-nitro-butanamide; and a compound being 4-(4-fluoro-2-methyl- phenyl)-5-nitro-3,4-dihydro-1H-pyridin-2-one.
The present invention relates to a process for producing 4- (4-fluoro-2-methyl-phenyl) -5-nitro-1H-pyridin-2-one, a key intermediate of 2- [3, 5-bis (trifluoromethyl) phenyl] -N- {4- (4-fluoro-2-methylphenyl) -6- [ (7S, 9aS) -7- (hydroxymethyl) hexahydropyrazino [2, 1-c][1, 4] oxazin-8 (1H) -yl] pyridin-3-yl} -N, 2-dimethylpropanamide (elinzanetant). Further, the invention relates to a compound of Formula (VII), wherein R1144-alkyl or optionally substituted phenyl; a compound being 3- (4-fluoro-2-methyl-phenyl) -4-nitro-butanamide; and a compound being 4- (4-fluoro-2-methyl-phenyl)-5-nitro-3,4-dihydro-1H-pyridin-2-one.
The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
The invention relates to a lettuce plant (Lactuca sativa L.) comprising a resistance QTL which confers dual resistance to Fusarium oxysporum f.sp lactucae race Fol-1 and race Fol-4, wherein the QTL is located on chromosome 7. The invention further provides seeds, progeny, propagation material and food products from the plant.
A fluid injector system for reconstituting a solute contrast media and injecting reconstituted contrast media solution resulting therefrom includes a first syringe containing a diluent, a container containing the solute contrast media, a first valve configured to provide selective fluid communication between the container and the first syringe, and a controller. The controller is programmed or configured to deliver the diluent into the container to reconstitute the solute contrast media into a reconstituted contrast media solution, and deliver the reconstituted contrast media solution into an administration line configured to be fluidly connectable to a patient.
The present invention covers a sequential one-pot synthesis for preparing 4-(4-cyano-2-methoxy-phenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide according to formula (XIII). In particular, in the sequential one-pot synthesis (4R)-4-(4-cyano-2-methoxy-phenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide according to formula ent-(I) is used as starting material to obtain 4-(4-cyano-2-methoxy-phenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide according to formula (XIII) via electrochemical oxidation and electrochemical reduction.
The present disclosure provides engineered type V nucleases suitable for editing eukaryotic genomic DNA, as well as methods of producing the nucleases, systems comprising the nucleases, as well as methods of using the nucleases and systems to edit eukaryotic genomic DNA.
The present disclosure relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements R1, R2, R3, R4 and R5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.
The present disclosure relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements R1, R2, R3, R4 and R5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.
A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Cosmetics (for topical and oral application, and eye drops), for treatment of the skin, nose and eyes, including skin care products for use during pregnancy and while breastfeeding, and for babies, for the care of wounds and scars and for allergic and dry skin irritations, except hair care and hair styling products of all kinds, depilatories and hair dyes. Pharmaceuticals; medical preparations.
The present invention relates to a process for preparing of pure (3S)-Pyrrolidin-3-ol (“the base”) of formula (I), and the preparation of the corresponding (3S)-Pyrrolidin-3-ol hydrochloride (“the hydrochloride”) of formula (II).
The present invention relates to a process for preparing of pure (3S)-Pyrrolidin-3-ol (“the base”) of formula (I), and the preparation of the corresponding (3S)-Pyrrolidin-3-ol hydrochloride (“the hydrochloride”) of formula (II).
A system and method for promoting and safeguarding the wellbeing of patients in relation to a fluid injection may obtain patient data; determine, based on the patient data, an initial risk prediction for a patient for a fluid injection to be administered to the patient, the initial risk prediction including a probability that the patient experiences at least one adverse event in response to the fluid injection; provide, to a user device, before the fluid injection is administered to the patient, the initial risk prediction; determine, after the fluid injection is started, sensor data associated with the patient; determine, based on the sensor data determined after the fluid injection is started, a current risk prediction including a probability that the patient experiences the at least one adverse event in response to the fluid injection; and provide, to the user device, the current risk prediction.
A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/28 - Bioelectric electrodes therefor specially adapted for particular uses for electrocardiography [ECG]
A61B 5/296 - Bioelectric electrodes therefor specially adapted for particular uses for electromyography [EMG]
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
Provided are topical analgesic gel compositions having relatively high payloads of menthol and camphor by micro-emulsion technology and methods of preparing topical analgesic gel compositions having relatively high payloads of menthol and camphor. Topical analgesic gel compositions may include from 12 to 16 wt. % menthol; from 4 to 8 wt. % camphor; from 0.1 to 2 wt. % carbomer; and 60 to 70 wt. % solvent. Topical analgesic gel compositions can have a viscosity from 60,000 to 110,000 centipoise.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
15.
SYSTEM AND METHOD UTILIZING AN INTEGRATED CAMERA WITH A FLUID INJECTOR
A fluid injector system configured for use in administering at least one fluid to a patient, the fluid injector system including at least one image capture device configured for capturing image data in an environment surrounding the fluid injector system; and a control device comprising at least one processor programmed or configured to receive, with the at least one processor, the image data captured by the at least one image capture device; determine, with the at least one processor, whether the received image data comprises at least one predetermined characteristic; and perform, with the at least one processor, at least one action in response to determining whether the received image data comprises at least one predetermined characteristic.
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/42 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
16.
INCREASED NITROGEN FIXATION USING BACTERIA WITH IMPROVED AMMONIA SECRETION
Herbaspirillum bacterial strains are engineered to express or overexpress one or more proteins and/or attenuate expression of or delete one or more genes involved in nitrogen fixation and its regulation. This enables the diazotrophic bacteria to secrete more ammonia. The engineered bacteria arc introduced to agricultural plants, or seeds for growing such, forming a symbiotic relationship that results in increased nitrogen availability to the plant and improved plant agronomic traits.
The computer-implemented methods, computer systems and non-transitory computer readable storage medium disclosed herein relate to predicting the bioavailability for at least one agricultural active ingredient with a trained machine learning model based on spectral data of soil of an agricultural field.
G01N 21/3554 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for determining moisture content
G01N 21/3563 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing solidsPreparation of samples therefor
G01N 21/359 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
The invention also refers to finerenone or a hydrate, solvate, pharmaceutically acceptable salt thereof, or a polymorph thereof for use in the prevention or treatment of chronic kidney disease in a patient with type I diabetes, comprising administering to the patient a therapeutically effective amount of finerenone or a hydrate, solvate, pharmaceutically acceptable salt thereof, or a polymorph thereof.
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
The present invention deals with the selection of antibodies and/or antibody fragments in a selection method. Subjects of the present invention are a method, a system and a computer program product for generating score values for pairs of genes which encode the variable domains of light and heavy chains of antibodies and/or antibody fragments. Antibodies and/or antibody fragments can be selected on the basis of the score values.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Computationally implemented methods, computing systems and computer program products disclosed herein relate to the calculation of risk values for crop plant phytotoxicity based on the classification of digital images into vegetation classes, including additional agronomic data and the provision of agricultural recommendations based on these risk values.
The invention relates to novel herbicidal active compound combinations which comprise substituted isoxazolincarboxamides or agrochemical acceptable salts thereof and substituted aminopyridines and aminopyrimidines. They can be used with particularly good results for the control of weeds in various crops of useful plants.
A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
Herbal Composition for Activation of the Endocannabinoid System The present invention relates to herbal compositions and methods to activate the endocannabinoid system in order to alleviate stress and its attendant adverse health effects.
The present invention relates to compositions containing herbicidally active compounds (A) and (B), wherein (A) represents one or more compounds of the general formula (I) or agrochemically compatible salts thereof [component (A)], and (B) represents one or more herbicides [component (B)]. The application further relates to a method and to the use of the herbicidal composition according to the invention for control of harmful plants or for growth regulation.
A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
A01N 47/06 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having no bond to a nitrogen atom containing —O—CO—O— groupsThio-analogues thereof
3-Heterocyclylbenzamides of the formula (I) are described as herbicides. In this formula (I), X, Y, Z and Rx are radicals such as alkyl, cycloalkyl, haloalkyl and halogen.
A01N 43/713 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with four or more nitrogen atoms as the only ring hetero atoms
C07D 261/04 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
29.
SUBSTITUTED ISOPHTHALIC ACID DIAMIDES AND USE THEREOF AS HERBICIDES
Isophthalamides of the formula (I) are described as herbicides. In this formula (I), X, Y, Z1, Z2 and Rx are radicals such as alkyl, cycloalkyl, haloalkyl and halogen.
A01N 43/713 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with four or more nitrogen atoms as the only ring hetero atoms
C07C 235/42 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
C07D 257/06 - Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
30.
PRESSURE JACKETS AND SYRINGE RETENTION FEATURES FOR ANGIOGRAPHY FLUID INJECTORS
An assembly for retaining a pressure jacket and a syringe on a fluid injector, the assembly including a base plate comprising a body; at least a first retaining arm and a second retaining arm operatively mounted on the body of the base plate, the first retaining arm having a first retaining surface at a distal end thereof and the second retaining arm having a second retaining surface at a distal end thereof, wherein the first retaining surface and the second retaining surface are configured for abutting a distal surface of at least one of the pressure jacket and the syringe; a linkage assembly operatively connected to at least one of the first retaining arm and the second retaining arm, wherein the linkage assembly is configured to move at least one of the first retaining arm and the second retaining arm between at least a first open position and a closed position.
Sulfonimidoylbenzamides of the formula (I) are described as herbicides. In this formula (I), X, W, Z, R, R' and R" are radicals such as alkyl, cycloalkyl, haloalkyl and halogen.
A01N 43/82 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with three hetero atoms
The present invention relates to compositions comprising herbicidally active compounds (A) and (B), wherein (A) represents one or more compounds of the general formula (I) or agrochemically compatible salts thereof [component (A)], and (B) represents one or more herbicides [component (B)]. The application further relates to a process and to the use of the herbicidal composition of the invention for the control of harmful plants or for growth regulation.
A01N 47/38 - Ureas or thioureas containing the groups N—CO—N or N—CS—N containing the group N—CO—N where at least one nitrogen atom is part of a heterocyclic ringThio-analogues thereof
3-Acylbenzamides of the formula (I) are described as herbicides. In this formula (I), X, Y, Z and Rx are radicals such as alkyl, cycloalkyl, haloalkyl and halogen.
A01N 43/713 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with four or more nitrogen atoms as the only ring hetero atoms
C07D 257/06 - Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
Arylcarboxamides of the formula (I) are described as herbicides. In this formula (I), X, Y, Z and Rx are radicals such as alkyl, cycloalkyl, haloalkyl, and halogen.
A01N 43/713 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with four or more nitrogen atoms as the only ring hetero atoms
C07C 317/02 - SulfonesSulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
C07D 257/06 - Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
A fluid path connector for a medical fluid delivery system, the fluid path connector including a first connector element comprising a body, a first lumen, a first flexible leg, and a second flexible leg, and a second connector element comprising a body defining an undercut, a second lumen, a channel defined in the body, and at least one sealing element positioned within the channel, in which the first flexible leg comprises a first flange and the second flexible leg comprises a second flange, and in which, upon engagement of the first connector element with the second connector element, the first flange and the second flange engage with the undercut of the body of the second connector element to prevent disengagement of the first connector element and the second connector element.
The present invention relates to high dose VEGF antagonists for the treatment of angiogenic eye disorders secondary to retinal vein occlusion – such as vascular permeability, macular edema, retinal hemorrhage, and neovascularization – and for the treatment of retinal vein occlusion. The treatments include high doses of aflibercept and lengthening intervals between doses.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
What is described herein relates to a method for optimizing purification conditions of a protein of interest comprising: a) prediction of filtration performance of a protein of interest based on the hydrophobicity of said protein of interest and/or b) filtration of a protein of interest wherein the protein of interest has an isoelectric point in the range of between 3.0 and 7.5 and the filtration is earned out at a pH above the isoelectric point.
A system for providing a quick response (QR) code associated with an injection system is disclosed. The system includes the injection system and at least one processor. The at least one processor is programmed or configured to: receive data associated with the injection system; generate a network resource based on the data associated with the injection system, wherein, when generating the network resource, the at least one processor is programmed or configured to encode the data associated with the injection system into the network resource; generate a QR code based on the network resource; and display the QR code on a display screen of the injection system.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G06K 19/06 - Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietary food preparations for medical purposes; medical
preparations for use as additives for human consumption;
medical preparations and substances; pharmaceutical
preparations.
42.
GENERATION OF ARTIFICIAL CONTRAST-ENHANCED RADIOLOGICAL IMAGES
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01R 33/28 - Details of apparatus provided for in groups
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
The present invention relates to regimens for the treatment of angiogenic eye disorders secondary to retinal vein occlusion, such as vascular permeability, macular edema, retinal hemorrhage, and neovascularization, and for treatment of retinal vein occlusion, characterized by high doses of aflibercept and lengthening intervals between doses.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present invention relates to compositions comprising herbicidally active compounds (A) and (B), where (A) represents one or more compounds of the general formula (I) or agrochemically compatible salts thereof [component (A)], and (B) represents one or more herbicides [component (B)]. The application also relates to a process and to the use of the herbicidal composition according to the invention for controlling undesirable plants or regulating plant growth.
irir3.4, KCNJ5) inhibitory compounds, the preparation thereof and the use thereof for the treatment and/or prevention of diseases. These compounds can be used for the treatment and/or prevention of cardiovascular disorders. In one Example the disorder can be atrial fibrillation (AF) and/or other related cardiac arrhythmias.
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
47.
BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS CAPABLE OF ALLEVIATING AND PREVENTING ALLERGIC RHINITIS, AND USE THEREOF
Provided are a bifidobacterium longum subsp. infantis capable of alleviating and preventing allergic rhinitis, and a use thereof, relating to the technical fields of microorganisms and medicine. The bifidobacterium longum subsp. infantis CCFM111 can alleviate allergic reactions in allergic mice, and alleviate and prevent allergic disorders in patients with perennial allergic rhinitis. Specifically: (1) the bifidobacterium longum subsp. infantis CCFM111 alleviates weight loss and symptoms caused by allergies in mice, reduces pulmonary inflammation infiltration, lowers serum OVA-sIgE and total IgE levels, and regulates the expression of pro-inflammatory and anti-inflammatory factors. (2) The bifidobacterium longum subsp. infantis CCFM111 alleviates allergic symptoms and reduces medication scores in patients, increases the proportion of symptom-free days of patients, lowers the serum sIgE levels against dermatophagoides farinae and dermatophagoides pteronyssinus in patients, and regulates the expression of cytokines in the serum and nasal lavage fluid of patients. Therefore, the bifidobacterium longum subsp. infantis CCFM111 has broad prospects for application in the preparation of a product for preventing and/or treating allergic rhinitis.
Systems, methods, and computer programs disclosed herein relate to training and using a machine learning model to predict compositions and/or properties of formulations, in particular of active ingredient formulations.
The present invention relates to the technical field of the marking of articles by means of optically readable codes and of decoding the codes. Such a code is introduced into a surface of an article. The code is decoded on the basis of a transformed captured image of the code. The transformed captured image is generated from at least one captured image of the code using a machine learning model. The model is trained to generate a transformed captured image from at least one captured image and the readout of the optically readable code leads to less decoding errors than the readout of the code in the at least one captured image. The present invention relates to a method for training the machine learning model and to a method, a system and a computer program product for decoding a code using the trained machine learning model.
G06K 7/14 - Methods or arrangements for sensing record carriers by electromagnetic radiation, e.g. optical sensingMethods or arrangements for sensing record carriers by corpuscular radiation using light without selection of wavelength, e.g. sensing reflected white light
The present invention relates to a process for preparing (4S)-24-chloro-4-ethyl-73-fluoro-35- methoxy-32,5-dioxo-14-(trifluoromethyl)-32HH-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola- 2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide (I) from (Z)-2-bromobut-2-enoic acid (XXII), 4- amino-2-fluorobenzamide (XII) and 4-{5-chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1- yl]phenyl}-5-methoxypyridin-2(1H)-one (XV) with an enantioselective hydrogenation of the 5 double bond in the last synthesis step.
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07C 237/30 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
The present invention relates to a process for preparing (4S)-24-chloro-4-ethyl-73-fluoro-35- methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola- 2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide (I) from 2,5-dimethoxypyridine (II), 1-(2-bromo- 4-chlorophenyl)-4-(trifluoromethyl)-1H-1,2,3-triazole (IV), 4-amino-2-fluorbenzamide (IX) and (2R)-2-bromobutanoic acid - N-cyclohexylcyclohexanamine (XI).
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
The present disclosure relates to monitoring arthropods on the basis of captured images. The subject matter of the present disclosure comprises a device, a system, and a method.
Medical instruments; medical devices; medical devices for the delivery of contraceptives; non-chemical contraceptives for delivery via devices; contraceptives (non-chemical) for the delivery via device; none of the aforementioned goods being Cardiac ablation catheters.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietary food preparations for medical purposes; medical
preparations for use as additives for human consumption;
medical preparations and substances; pharmaceutical
preparations.
The invention relates to a process for distillative recovery of 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) from an initial mixture comprising 1,1,1,3,3,3-hexafluoro-2-propanol and at least one 4-substituted 1,2,3,4-tetrahydroquinoline, wherein a protic solvent selected from the group consisting of water, alcohols having a boiling point at 1 bar of 115° C. or less, and mixtures thereof is added to the initial mixture to obtain a distillation mixture, and the distillation mixture is subjected to distillation.
C07C 29/80 - SeparationPurificationStabilisationUse of additives by physical treatment by distillation
66.
BROMINE- OR IODINE-PARA-SUBSTITUTED [(1,5-DIPHENYL-1H-1,2,4-TRIAZOL-3-YL)OXY]ACETIC ACID DERIVATIVES AND THEIR SALTS, AGENTS FOR PROTECTING USEFUL PLANTS OR CROP PLANTS COMPRISING THEM, METHODS FOR PRODUCING THEM AND THEIR USE AS SAFENERS
The invention relates to bromine- or iodine-para-substituted [(1,5-diphenyl-1H-1,2,4-triazol-3-yl)oxy]acetic acid derivatives and their salts, to agents for protecting useful plants or crop plants comprising them, to methods for producing them and to their use as safeners. The present invention relates to protection compounds and agents for useful plants, which compounds and agents comprise specific compounds as safeners for reducing phytotoxic effects of agrochemicals, especially herbicides. The invention relates more particularly to bromine- or iodine-para-substituted [(1,5-diphenyl-1H-1,2,4-triazol-3-yl)oxy]acetic acid derivatives of the general formula (I) and their salts, to methods for producing them and to the their use as protection compounds (safeners) for useful plants.
A01N 25/32 - Ingredients for reducing the noxious effect of the active substances to organisms other than pests, e.g. toxicity reducing compositions, self-destructing compositions
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
67.
SOLVENT-FREE FORMULATIONS OF LOW-MELTING ACTIVE INGREDIENTS
The present disclosure relates to solvent-free aqueous suspension concentrates and to solvent-free solid water-dispersible formulations comprising one or more low-melting active ingredients, and to processes for production thereof. The formulations according to the disclosure are suitable for the field of plant protection.
A01N 25/32 - Ingredients for reducing the noxious effect of the active substances to organisms other than pests, e.g. toxicity reducing compositions, self-destructing compositions
A01N 47/36 - Ureas or thioureas containing the groups N—CO—N or N—CS—N containing the group N—CO—N directly attached to at least one heterocyclic ringThio-analogues thereof
What is described herein relates to automated aseptic method for formulation of cells comprising providing a container with a filling volume in the range of between of 0.01-50 ml, filling the container with a cell suspension and a solution, closing the container, mixing the cell suspension and the solution to generate a final suspension, wherein the container is a final product container
The present disclosure relates to the monitoring of arthropods on the basis of captured images. The present disclosure provides a system, a kit and a method. The system comprises a main body (10) having a receiving surface (11) for receiving a sheet provided with adhesive, a holding device (30) for receiving an IoT device comprising a camera, spacer means (40), wherein the spacer means (40) fix the holding device (30) at a distance from the receiving surface (11) of the main body (10), and an enclosure (20) between the spacer means and the main body for protecting the receiving surface from environmental influences. The enclosure (20) and the receiving surface (11) define a volume and/or delimit this volume at least in part. The holding device (30) is outside the volume.
The present embodiments relate to cell confluency estimation and manufacturing. Subject matter of the present embodiments provides computer-implemented methods, computer systems and computer-readable storage media for predicting the results of image-based cell confluency estimation and manufacturing methods.
G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
71.
WET GRANULATION PLATFORM TECHNOLOGY TO MANUFACTURE SOFT TABLETS/CHEWS
A composition including wet granules is provided herein, where the wet granules include pectin, xanthan gum, one or more sweetener, a glycerin-water mixture, and one or more active pharmaceutical ingredient (API), and a lubricant is optionally present on one or more of the wet granules. Also provided herein is a gummy product including pectin, xanthan gum, one or more sweetener, a glycerin-water mixture, and one or more API. Also provided herein is a method of making a gummy product including hydrating a powder blend with a glycerin-water mixture to form wet granules, optionally coating the wet granules with a lubricant, and compressing the wet granules to form the gummy product, where the powder blend includes pectin, xanthan gum, one or more sweetener, and one or more API.
A23G 3/36 - Sweetmeats, confectionery or marzipanProcesses for the preparation thereof characterised by the composition
A23G 3/42 - Sweetmeats, confectionery or marzipanProcesses for the preparation thereof characterised by the composition characterised by the carbohydrates used, e.g. polysaccharides
A23G 3/48 - Sweetmeats, confectionery or marzipanProcesses for the preparation thereof characterised by the composition containing plants or parts thereof, e.g. fruits, seeds, extracts
The present invention covers the use of chymase inhibitors in general and more in particular substituted bicyclically substituted uracils of general formula (I) as described and defined herein, and 3-methylbenzo-[b]thiophene)-2-sulfonamido derivatives of general formula (II) for manufacturing pharmaceutical compositions for the treatment or prophylaxis of stroke, pulmonary embolism, deep or superficial vein thrombosis, thrombotic microangiopathy, thrombotic microangiopathy in hypercoagulable states after infection, inflammation, transplantation, disseminated intravascular coagulation, vaccine-induced immune thrombotic thrombocytopenia, vascular access site thrombosis or occlusion.
The present disclosure relates to monitoring arthropods on the basis of captured images. The subject matter of the present disclosure is a computer-implemented method, a device, and a computer program.
The present disclosure relates to heterocyclyl pyridazine compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.
A01N 43/88 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms six-membered rings with three ring hetero atoms
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
Provided herein is a system for delivering a therapeutic composition to a patient, including: a container configured to hold a therapeutic composition; at least one powered drive in operative connection with the container; a plurality of sensors including at least two of (i) a pressure sensor, (ii) a flow sensor, (iii) a counting sensor, (iv) a site sensor, (v) a temperature sensor, (vi) a chemical sensor, and (vii) at least one physiological sensor; and at least one processor programmed or configured to receive the data from the plurality of sensors and, control the at least one powered drive to inject the therapeutic composition into the patient at a desired flow rate whose magnitude depends on the data received from the plurality of sensors.
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
79.
SYSTEM, METHOD, AND COMPUTER PROGRAM PRODUCT FOR OCCLUSION DETECTION AND IMPROVED PRESSURE LIMITING BEHAVIOR FOR FLUID INJECTOR DEVICES
A system and computer program product are disclosed for occlusion detection and/or pressure limiting in a fluid injector system. A fluid injector system includes at least one fluid injector device, one or more drive components, and a control device. The control device includes at least one processor programmed provide instructions to the fluid injector system to deliver fluid at a predetermined fluid flow rate, determine a first fluid pressure measurement within the fluid injector device at a first time, determine a second fluid pressure measurement at a second time, determine a pressure differential between the first fluid pressure measurement and the second fluid pressure measurement, calculate a change in compliance volume based on the determined pressure differential, compare the calculated change in compliance volume with the predetermined fluid flow rate, repeat the steps throughout the fluid injection procedure, and determine whether an occlusion or a partial occlusion has occurred.
The present disclosure relates to new manganese (Mn2+) chelate compounds, to methods of preparing said compounds, to the use of said compounds as contrast agents in diagnostic imaging such as magnetic resonance imaging (MRI) and to their use in a mammalian body.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
Described herein are DMSO formulations and methods for cell therapy. Methods of treating a cell with these formulations are also provided. The embodiments provide a formulation that maintains the suspension and viability of a T-cell during cell therapy (CT) manufacturing and through a cryopreservation thaw cycle, including dimethyl sulfoxide (DMSO); sucrose or trehalose; human semm albumin (HSA); and dextran 40 or hydroxyethyl starch (HES). wherein the formulation maintains the suspension and viability of T-cells during CT manufacturing and through a cryopreservation thaw cycle. The embodiments provide a method for maintaining a suspension and cell viability, including subjecting a T-cell during a cell therapy manufacturing cryopreservation thaw cycle to a formulation including DMSO; sucrose or trehalose; human semm albumin (HSA); and polysaccharide or HES wherein the formulation maintains the suspension and viability of a T-cell during cell therapy manufacturing and through a cryopreservation thaw cycle.
PaenibacillusPaenibacillus bacterial strains are engineered to express or overexpress (i) one or more proteins (pyruvate ferredoxin oxidoreductase, flavodoxin, and/or ferredoxin) involved in the electron transport chain, (ii) the DUF protein and/or (iii) gene products of the suf operon. This enables a greater rate/level of nitrogen fixation by the diazotrophic bacteria. The engineered bacteria are introduced to agricultural plants, or seeds for growing such, forming a symbiotic relationship that results in increased nitrogen availability to the plant and improved plant agronomic traits.
